Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

Recruiting now

Conditions studied: Primary Tumor, Colon Tumor

In brief

Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.

Key facts

Study ID

NCT05038358

Run by

University Hospital, Grenoble

People needed

60

Starts

2022-12-12

Expected to finish

2030-12-31

Last updated by the study team

2026-05-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female over 18 years old.
• Managed at the CHUGA for a colorectal adenocarcinoma
• With an indication for immediate surgical resection as part of the care.
• Patient naive from neo-adjuvant chemotherapy
• Patient did not object to the CRC-ORGA-2 study

You may not qualify if…

• Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress).
• Patients with positive HIV, HBV, HCV serology.

Where it is running

• University Hospital of Grenoble Alpes — Grenoble, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.